NCT06424834RecruitingPhase 2/3
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study
Source: ClinicalTrials.gov · Last updated 27 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 12 May 2024
- Start date
- 10 Oct 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Stanford University
- Diseases
- Coronary artery disease
- NCT number
- NCT06424834
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 150
- From 10 Oct 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute coronary syndrome less than one week prior to enrolment
Other illness
- Baseline heart rate \< 55 bpm
Lab values
- Contraindications to beta-blockers or calcium channel blockers
Other
- Cardiomyopathy
- Baseline systolic blood pressure \< 95 mmHg
Who the study is looking for
- All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study.
- Specific inclusion criteria for randomization:
- Absence of significant epicardial coronary artery disease on angiography
- Fractional flow reserve \> 0.80
- And ≥ 1 of the following:
- Epicardial coronary spasm on acetylcholine testing
- Microvascular spasm on acetylcholine testing
- Coronary flow reserve \< 2.5
- Index of microcirculatory resistance ≥ 25
- Myocardial bridge on intravascular ultrasound with dobutamine resting full-cycle ratio ≤ 0.76
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford hospital Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.